Mostrando entradas con la etiqueta Insulinas. Mostrar todas las entradas
Mostrando entradas con la etiqueta Insulinas. Mostrar todas las entradas

jueves, 14 de febrero de 2019

Insulinas / Insulins

Febrero 10,  2020 No. 3335

Convocatoria para Capítulos sobre Anestésicos Locales
Call for Book Chapters on Local Anesthetics
Guía definitiva de insulina
Ultimate Guide to Insulin
King Khalid University
IntechOpen
The book presents a qualitative and quantitative approach to understand, manage and enforce the integration of insulin into diabetes mellitus. Utilizing a sound theoretical and practical foundation and illustrating procedural techniques through scientific examples, the book bridges the gap between insulin and diabetes mellitus management. Detailed procedures have been omitted because of the variety of equipment and commercial kits used in today's clinical laboratories.
Análogos de la insulina de acción corta versus insulina humana regular en la glucosa posprandial e hipoglucemia en la diabetes mellitus tipo 1: una revisión sistemática y un metanálisis.
Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis.
Diabetol Metab Syndr. 2019 Jan 3;11:2. doi: 10.1186/s13098-018-0397-3. eCollection 2019.
Abstract
INTRODUCTION: Strict glucose control using multiple doses of insulin is the standard treatment for type 1 diabetes mellitus (T1DM), but increased risk of hypoglycemia is a frequent drawback. Regular insulin in multiple doses is important for achieving strict glycemic control for T1DM, but short-acting insulin analogues may be better in reducing hypoglycemia and postprandial glucose levels....... CONCLUSIONS: Short-acting insulin analogues are superior to regular human insulin in T1DM patients for the following outcomes: total hypoglycemic episodes, nocturnal hypoglycemia, severe hypoglycemia, postprandial glucose, and HbA1c.
KEYWORDS: Aspart insulin; Diabetes mellitus; Glulisine insulin; Insulin; Lispro insulin; Meta-analysis; Systematic review; Type 1 diabetes
Insulinas concentradas en la práctica clínica actual.
Concentrated insulins in current clinical practice.
Diabetes Res Clin Pract. 2018 Dec 21;148:93-101. doi: 10.1016/j.diabres.2018.12.007. [Epub ahead of print]
Abstract
New concentrated insulins (exceeding 100 units/mL) and dedicated devices have recently become available, offering new treatment options for people with diabetes, for basal and prandial insulin supplementation. The concentrated insulin formulations range from 2-fold concentration (insulin lispro 200 units/mL) with rapid-acting prandial action to 5-fold concentration (human regular insulin, 500 units/mL) with basal and short-acting prandial actions. Long-acting basal insulins include degludec 200 units/mL and glargine 300 units/mL. Concentrated insulins have been developed with the goal of easing insulin therapy by reducing the volume and number of injections and in some cases making use of altered pharmacokinetic and pharmacodynamic properties. This review summarizes the unique characteristics of each concentrated insulin to help healthcare providers and people with diabetes understand how to best use them.
KEYWORDS: Concentrated; Diabetes; Insulin; Pharmacokinetic; Prandial
Congresos Médicos por Especialidades en todo Mundo
Medical Congresses by Specialties around the World
Safe Anaesthesia Worldwide
Delivering safe anaesthesia to the world's poorest people
Like us on Facebook   Follow us on Twitter   Find us on Google+   View our videos on YouTube 
Anestesiología y Medicina del Dolor

52 664 6848905